RVL Pharmaceuticals plc (RVLP)
Market Cap | 111.48M |
Revenue (ttm) | 49.72M |
Net Income (ttm) | -51.69M |
Shares Out | 106.17M |
EPS (ttm) | -0.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 16,195 |
Open | 1.00 |
Previous Close | 1.02 |
Day's Range | 1.00 - 1.09 |
52-Week Range | 0.98 - 2.99 |
Beta | 1.10 |
Analysts | Buy |
Price Target | 3.76 (+258.1%) |
Earnings Date | May 11, 2023 |
About RVLP
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed i... [Read more]
Financial Performance
In 2022, RVLP's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RVLP stock is "Buy." The 12-month stock price forecast is $3.76, which is an increase of 258.10% from the latest price.
News

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update
-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, o...

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update
Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales
-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for ful...

RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Exe...

RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices...

RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales
--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales ...

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exe...

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc
DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nas...

RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update
-- Second quarter 2022 UPNEEQ ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings --

RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closin...

RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update
Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET

RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results
-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product s...

RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company's Annua...

RVL Pharmaceuticals plc to Present at Upcoming Conferences
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exec...

RVL Pharmaceuticals PLC (RVLP) Reports Q1 Loss, Tops Revenue Estimates
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 48% and 197.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update
First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021

UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards"
BRIDGEWATER, N.J. , May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company") announced today that its FDA approved ptosis drug Upneeq® (oxymetazoline hydrochloride o...

RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update
Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET

UPNEEQ® Wins "Best in Innovation" Award from New Beauty
12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S. FDA approved acquire...

RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results
-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guida...

RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates
RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 10.34% and 7.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto...

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Preliminary First Quarter 2022 UPNEEQ® Revenue Estimate and Business Update
Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch
-- Conference call to be held March 30, 2022, at 4:30 p.m. ET -- -- Conference call to be held March 30, 2022, at 4:30 p.m. ET --